Persistent PTC sees slim chances on DMD drug decrease further

27 September 2017
2019_biotech_test_vial_discovery_big

Markets reacted accordingly on Tuesday as PTC Therapeutics (Nasdaq: PTCT) suffered the latest blow to its hopes to gain approval in the USA for Translarna (ataluren) as a treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD).

The US drugmaker saw its share price slide by 14% to $16.81 after the publication of an FDA report that raises concerns over the data submitted to show Translarna’s efficacy in nmDMD patients, who make up around 10 to 15% of those with DMD.

"Ultimately, no positive results from any prospectively planned analyses that are persuasive"

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology